People News

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015

3.0 from 4 votes
Monday, November 23, 2015

NORWOOD, MA - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at two upcoming investor conferences in December.

Event: 27th Annual Piper Jaffray Healthcare Conference
Date: Tuesday, December 1, 2015
Time: 8:30 a.m. Eastern Time
Location: New York Palace Hotel, New York City

Event: Oppenheimer 26th Annual Healthcare Conference
Date: Tuesday, December 8, 2015
Time: 10:20 a.m. Eastern Time
Location: Westin Grand Central Hotel, New York City

Dr. Cohen will provide a corporate overview and discuss the progress of the Company's three clinical trial programs for Resunab™. Resunab is a novel synthetic oral drug intended to resolve chronic inflammation and halt fibrosis. The drug is currently being evaluated in three separate Phase 2 clinical studies in cystic fibrosis ("CF"), diffuse cutaneous systemic sclerosis, and skin-predominant dermatomyositis. Corbus expects to report top-line safety and efficacy results from these Phase 2 studies starting at the end of 2016.

Live webcasts of both presentations will be available by accessing the IR Calendar the Investors section of the Corbus website ( The webcast replays will be available approximately two hours after each presentation ends and will be accessible for one month.

About Resunab™
Resunab™ is a novel synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in pre-clinical models of inflammation and fibrosis. Resunab triggers the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of pro-inflammatory eicosanoids and cytokines. Resunab has direct effects on fibroblasts to halt tissue scarring. In effect, Resunab triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunab™, is a novel synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation, bacterial infections, and fibrotic processes. Resunab is currently in Phase 2 studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis and skin-predominant dermatomyositis.

For more information, please visit and connect with the Company on Twitter, LinkedIn, Google+ and Facebook.

Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: Email Contact

Media Contact
David Schull or Marissa Goberdhan
Russo Partners, LLC
Phone: +1 (858) 717-2310

Source: Corbus Pharmaceuticals Holdings, Inc.
3.0 from 4 votes
Free Newsletter
Related Videos